

Article scientifique

Article

2019

Accepted version

Open Access

This is an author manuscript post-peer-reviewing (accepted version) of the original publication. The layout of the published version may differ .

Evaluation of the quality of guidelines for assisted reproductive technology using the RIGHT checklist: A cross-sectional study

Xiao, Yujie; Jiang, Li; Tong, Yajing; Luo, Xufei; He, Jianghua; Liu, Lian; Gong, Chao; Ke, Lixin; Yang, Liu; Zhou, Qi; Estill, Janne Anton Markus; Shen, Huan; Chen, Yaolong

How to cite

XIAO, Yujie et al. Evaluation of the quality of guidelines for assisted reproductive technology using the RIGHT checklist: A cross-sectional study. In: European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2019, vol. 241, p. 42–48. doi: 10.1016/j.ejogrb.2019.07.039

This publication URL: <https://archive-ouverte.unige.ch/unige:133084>

Publication DOI: [10.1016/j.ejogrb.2019.07.039](https://doi.org/10.1016/j.ejogrb.2019.07.039)

A cross-sectional study: Evaluation of the quality of guidelines for assisted reproductive technology using the RIGHT checklist

Yujie XIAO^{1*}, Li JIANG^{2*}, Yajing TONG³, Xufei LUO^{4,5}, Jianghua HE¹, Lian LIU¹, Chao GONG¹, Lixin KE⁶, Liu YANG⁷, Qi ZHOU^{4,5,6}, Janne Estill^{8,9}, Huan SHEN^{2#}, Yaolong CHEN^{4,5#}

- 1 The Second Medical School of Lanzhou University, Lanzhou Gansu 730000 , China;
- 2 Reproductive Medicine Center, Peking University People's Hospital , Peking 100000 , China;
- 3 School of Public Health of Lanzhou University, Lanzhou Gansu 730000, China;
- 4 Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou Gansu 730000, China;
- 5 Chinese GRADE Center, Lanzhou University, Lanzhou Gansu 730000, China ;
- 6 The first Medical School of Lanzhou University, Lanzhou Gansu 730000, China;
- 7 The Reproductive Medicine Special Hospital of the first hospital of Lanzhou University , Key Laboratory for Reproductive Medicine and Embryo, Gansu Province, Lanzhou Gansu 730000, China;
- 8 Institute of Global Health, University of Geneva, Switzerland;
- 9 Institute of Mathematical Statistics and Actuarial Science, University of Bern, Switzerland;

* Yujie Xiao and Li Jiang contributed equally to this paper.

Huan SHEN and Yaolong CHEN contributed equally to this paper. Correspondence to: Huan SHEN, Email: rmivf@sina.com, Peking University People's Hospital 11 Xizhimen South Street Xicheng District, Beijing, 100044. Yaolong CHEN, Email: chenyaolong21@163.com, phone number: +8613893104140, address: 199 Donggang W Rd, Chengguan District, Lanzhou, Gansu 730000, China.

Word count: 2498

ABSTRACT

Introduction In recent years, assisted reproductive technology (ART) has developed rapidly, leading to an increasing number of clinical practice guidelines in this field. However, the reporting quality of current clinical practice guidelines in ART is still unknown. **Objective** To evaluate the reporting quality of clinical practice guidelines in the field of ART using the RIGHT checklist.

Method Relevant guidelines were identified by electronic search of PubMed, Chinese Biomedical Literature Database (CBM), Wan Fang Database and Chinese National Knowledge Infrastructure (CNKI) from the beginning of the database to October, 2017. We also searched the websites of the guideline development organizations, including Guidelines International Network (GIN), National Guideline Clearinghouse (NGC) and the National Institute for Health and Care Excellence (NICE), as well as from two medical associations, including the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM). We used Google Scholar to find additional clinical practice guidelines (CPGs) as well. Two investigators searched the database, selected guidelines independently based on the inclusion criteria, and extracted the relevant information.

Result Fifteen guidelines (i.e. six developed by individual institutions and 9 by associations) were included. On average, 12.7 out of 35 items in the RIGHT standard (36.3%) were reported in each guideline. Five items were not reported by any of these guidelines. The reporting proportion of the seven domains (i.e. *Basic information; Background; Evidence; Recommendations; Review and*

quality assurance; Funding and declaration and management of interests; Other information) were 46.7%, 40.8%, 45.3%, 29.5%, 53.3%, 10.0%, 26.7%, respectively.

Conclusion At present, the reporting quality of guidelines for ART is poor, especially regarding the funding. In the future guideline development, more consideration should be given to reporting, dissemination and implementation.

Key words: Clinical practice guideline; Assisted reproductive technology; RIGHT

INTRODUCTION

Assisted reproductive technology (ART) refers to the interventions that include the in vitro handling of both human oocytes and sperm or of embryos for the purpose of reproduction. This includes, but is not limited to, in vitro fertilization (IVF) and embryo transfer (ET), intracytoplasmic sperm injection (ICSI), embryo biopsy, preimplantation genetic testing (PGT), assisted hatching, gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer, gamete and embryo cryopreservation, semen, oocyte and embryo donation, and gestational carrier cycles.^[1] Previous studies show that infertility affects one in seven couples in the UK ^[2,3]; it appears there has been no major change in its prevalence but many more couples are seeking help than previously^[3]. Because of the serious issue of infertility and the increasing needs for treatment, an increasing number of hospitals have set up infertility centers. The significant development of ART^[2] provided new approaches of the diagnosis and treatment of infertile patients worldwide.^[1] However, ART is not without dilemmas and debates, and the researchers still fail to reach consensus on many dimensions of the technology. In order to regulate ART and provide standard guidance for specialists in this area, clinical practice guidelines (CPGs) for ART have emerged.

Clinical practice guidelines are statements that include recommendations intended to optimize patient care. High-quality clinical practice guidelines can standardize clinicians' treatment behaviors, reduce the costs and improve the quality of healthcare.^[4] AGREE II is an evaluation tool developed for quality assessment and reporting, which has been widely used. ^[5-8] To evaluate the quality of the guidelines for assisted reproductive technology, some previous studies using AGREE II have already been published, which showed the poor quality of current guidelines.^[9,10] However, AGREE II was created by a small group of researchers, and did not separate out reporting and methodological quality of guidelines. The exact reporting quality of the guidelines is still unknown.

In 2016, the International Reporting Items for Practice Guidelines in Health Care (RIGHT) Working Group developed the RIGHT checklist to assist guideline developers in reporting guidelines. Because of the different purpose, structure, and content^[11], multifunction tools may not be optimal and must be distinguished from tools that address reporting and those that assess methodological quality. Thus, RIGHT is better than AGREE II when it is used to evaluate the reporting quality of guidelines. Nowadays, RIGHT has already been widely recognized as the reporting criteria for guidelines ^[12] and has been translated into several languages.^[13] This study aims to evaluate the reporting quality of guidelines for assisted reproduction through the RIGHT checklist, to inform the formulation of future ART-related guidelines.

METHOD

Searching methods

Relevant guidelines were identified by electronic search of PubMed, Chinese Biomedical Literature Database (CBM), Wan Fang Database and Chinese National Knowledge Infrastructure (CNKI) from the beginning of the database to October, 2017. We also searched the websites of the guideline

development organizations, including Guidelines International Network (GIN), National Guideline Clearinghouse (NGC) and the National Institute for Health and Care Excellence (NICE), as well as from two medical associations, including the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM). Google Scholar was also searched to find additional CPGs. Search strategies are included in Annex 1.

Inclusion and exclusion criteria

We included clinical practice guidelines which are based on evidence and related to assisted reproductive technology.

The following types of CPGs were excluded: (a) translation of guidelines; (b) guidelines related to psychology and ethics; and (c) older version of guidelines if an updated version was available.

Data extraction

Two investigators searched the database, selected guidelines independently and determined if the guidelines retrieved met inclusion criteria of this study. They then extracted the main characteristics of the guidelines. Disagreements between reviewers were resolved through consensus or consulting an independent expert adjudicator.

The RIGHT instrument was used to assess the eligible guidelines included in this study (Annex 2). This instrument contained 22 key items (35 items, if sub-items are calculated) categorized into the following seven domains: “*Basic information*”, “*Background*”, “*Evidence*”, “*Recommendations*”, “*Review and quality assurance*”, “*Funding and declaration and management of interests*”, and “*Other information*”.^[14] Before data collection, three training sessions about using the RIGHT checklist and four pilot tests of assessment were conducted in order to ensure that the standards of assessment were met. Quality assessment was performed independently by four trained reviewers, who independently reviewed the quality of each eligible guideline. Disagreements between reviewers were resolved through consensus or consulting an independent expert adjudicator.

Most items were rated with a dichotomous scale (i.e., ‘Reported’-Y or ‘Not Reported’-N). ‘Reported’ means that the relevant information was fully reported, whereas ‘Not Reported’ was assigned when the relevant information was completely missing. For items containing more than one content, for example, “*Indicate the strength of recommendations and the certainty of the supporting evidence*”, we included a third category, ‘Partially Reported’ (P), which was used when only part of the contents were reported. When the items did not apply to the guidelines, “Not applied (NA)” was used. We reported the results in absolute number and percentage of guidelines reporting each item. For each item, we also reported the numbers and percentage of items reported by each guideline. If the reporting proportion of a guideline was less than 50%, we considered that the reporting quality is low. Data was abstracted and analyzed with Excel 2013.

RESULTS

Guideline characteristics

A total of 5314 records were identified through database search. Thirty-six additional records were identified through the websites of guideline development organizations and Google Scholar. After screening, fifteen guidelines (i.e. seven guidelines developed by institution and eight guidelines developed by association.) that eventually met the inclusion criteria were included (Figure 1). The characteristics for each included guideline are presented in Table 1.

Table1. Characteristics of included guidelines

Serial number	Title	Published date	Developer	Nation	Published journal
01	Recommendations on the management of services for in vitro fertilisation from the WHO (regional office for Europe) 1990 ^[15]	1990	World Health Organization (WHO)	International	BMJ
02	Royal College of Obstetrics and Gynaecologists. Clinical Guideline no 4. The management of infertility in tertiary care ^[16]	2001	Royal College of Obstetrics and Gynaecologists (RCOG)	UK	BJU International
03	ESHRE PGD Consortium 'Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) ^[17]	2005	European Society of Human Reproduction and Embryology (ESHRE)	USA	Human Reproduction
04	Guidelines for the number of embryos to transfer following in vitro fertilization ^[18]	2008	the Society of Obstetricians and Gynaecologists of Canada (SOGC)	Canada	International Journal of Gynecology and Obstetrics
05	Guidelines on number of embryos transferred ^[19]	2009	Practice Committee of the Society for Assisted Reproductive Technology(PCSART) and the Practice Committee of the American Society for Reproductive Medicine(PCASRM)	USA	Fertility & Sterility
06	Human oocyte cryopreservation: Evidence for practice ^[20]	2009	Association of Clinical Embryologists(ACE) AND British Fertility Society(BFS)	UK	Human Fertility
07	Elective Single Embryo Transfer Following In Vitro Fertilization ^[21]	2010	the Joint Society of Obstetricians and Gynaecologist of Canada–Canadian Fertility(JSOGCCF) and Andrology Society Clinical Practice Guidelines Committee(ASCPGC)	Canada	Journal of Obstetrics & Gynaecology Canada
08	The Boston IVF Handbook of Infertility A Practical Guide for Practitioners who Care for Infertile Couples Third Edition ^[22]	2012	Boston IVF and Harvard Medical School	USA	Not published in journal
09	Mature oocyte cryopreservation a guideline ^[23]	2013	Practice Committee of the Society for Assisted Reproductive Technology(PCSART) and the Practice Committee of the American Society for Reproductive Medicine(PCASRM)	USA	Fertility & Sterility
10	Fertility problems: assessment and treatment ^[24]	2013	The National Institute for Health and Care Excellence(NICE)	UK	Not published in journal

11	Fertility: assessment and treatment for people with fertility problems ^[25]	2013	National Collaborating Centre for Women’s and Children’s Health(NCCWCH)	UK	Not published in journal
12	Pregnancy Outcomes After Assisted Human Reproduction ^[26]	2014	the Genetics Committee(GC)	Canada	J Obstet Gynaecol Can
13	Elective Single Embryo Transfer: an update to UK Best Practice Guidelines ^[27]	2015	The Association Of Clinical Embryologists(ACE) and The British Fertility Society(BFS)	UK	Human Fertility
14	Performing the embryo transfer: a guideline ^[28]	2017	Practice Committee of the American Society for Reproductive Medicine(PCASRM)	USA	Fertility & Sterility
15	[Guideline for diagnosis and treatment of infertility in advanced age women] ^[29]	2017	Chinese Society of Reproductive Medicine(CSRM)	China	Chinese Journal of Reproduction and Contraception

Table 2. The details of reporting quality																	
Domain	Item	Guidelines															Reporting
		WHO,	RCOG,	ESHRE,	SOGC,	PCSART,	ACE,	JSOGCCF,	Boston IVF,	PCSART,	NICE,	NCCWCH,	GC,	ACE,	PCASRM,	CSRM,	proportion
		1900	2001	2005	2008	2009	2009	2010	2012	2013	2013	2013	2014	2015	2017	2017	
Basic information	1a	Y	Y	Y	Y	Y	N	N	Y	Y	N	N	N	Y	Y	Y	66.7%
	1b	Y	N	N	N	Y	N	N	Y	Y	Y	Y	N	N	Y	N	46.7%
	1c	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	N	N	Y	Y	80.0%
	2	N	N	N	Y	N	Y	Y	N	N	N	Y	Y	Y	Y	N	46.7%
	3	N	N	N	N	N	N	P	P	N	P	Y	P	N	N	N	6.7%
	4	N	P	Y	N	N	Y	N	P	Y	N	N	N	Y	N	Y	33.3%
Reporting proportion		50.0%	33.3%	50.0%	50.0%	50.0%	50.0%	33.3%	33.3%	66.6%	33.3%	66.6%	16.7%	50.0%	66.7%	50.0%	
Background	5	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	93.3%
	6	N	P	N	P	P	P	P	P	N	N	P	P	P	P	P	0
	7a	N	Y	N	Y	N	Y	Y	Y	Y	Y	Y	Y	N	N	Y	66.7%
	7b	N	Y	N	Y	Y	N	Y	N	Y	Y	Y	Y	N	N	Y	60.0%
	8a	N	Y	N	N	Y	N	N	Y	Y	N	Y	N	N	Y	N	40.0%
	8b	N	N	N	N	N	N	N	N	N	N	Y	Y	N	N	Y	20.0%
	9a	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	0
	9b	N	N	N	Y	N	N	N	Y	Y	N	Y	Y	N	Y	Y	46.7%
Reporting proportion		12.5%	50.0%	0	50.0%	37.5%	25.0%	37.5%	50.0%	62.5%	37.5%	75.0%	62.5%	12.5%	37.5%	62.5%	
Evidence	10a	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	80.0%
	10b	N	N	N	N	N	P	N	N	N	N	Y	N	N	N	N	6.7%
	11a	Y	Y	Y	Y	Y	Y	Y	N	Y	N	Y	Y	Y	Y	Y	86.7%
	11b	N	N	N	N	N	N	N	NA	P	NA	P	N	N	NA	N	0
	12	N	Y	N	Y	N	Y	Y	N	N	N	Y	Y	Y	Y	N	53.3%
Reporting proportion		20.0%	60.0%	40.0%	60.0%	20.0%	60.0%	60.0%	20.0%	20.0%	20.0%	80.0%	60.0%	60.0%	60.0%	40.0%	

Recommendations	13a	Y	Y	P	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	93.3%
	13b	NA	NA	NA	Y	Y	NA	Y	NA	Y	Y	Y	Y	N	NA	NA	46.7%
	13c	NA	P	NA	Y	NA	P	Y	NA	P	NA	P	Y	P	P	NA	20.0%
	14a	N	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	13.3%
	14b	N	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	13.3%
	14c	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	6.7%
	15	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	13.3%
Reporting proportion		14.3%	28.6%	0	42.9%	28.6%	14.3%	71.4%	14.3%	28.6%	28.6%	85.7%	42.9%	14.3%	14.3%	14.3%	
Review and quality	16	N	N	N	Y	N	N	Y	N	Y	Y	Y	Y	Y	Y	N	53.3%
assurance	17	N	N	N	Y	N	N	Y	N	Y	Y	Y	Y	Y	Y	N	53.3%
Reporting proportion		0	0	0	100%	0	0	100%	0	100%	100%	100%	100%	100%	100%	0	
Funding and	18a	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	P	6.7%
declaration and	18b	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	N	NA	NA	NA	NA	0
management of	19a	N	N	N	N	Y	Y	N	N	N	N	N	N	Y	N	N	20.0%
interests	19b	N	N	N	N	N	N	N	N	Y	N	N	N	N	Y	N	13.3%
Reporting proportion		0	0	0	0	0	25.0%	0	0	0	0	25.0%	0	25.0%	25.0%	0	
Other information	20	N	Y	N	Y	N	N	N	Y	N	Y	N	N	Y	N	N	33.3%
	21	Y	Y	N	N	N	Y	N	N	Y	N	Y	N	Y	Y	N	46.7%
	22	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	0
Reporting proportion		33.3%	66.6%	0	33.3%	0	33.3%	0	33.3%	33.3%	33.3%	33.3%	0	66.6%	33.3%	0	

Reporting result of guidelines included

On average, 12.7 (36.3%) of the 35 items in the RIGHT standard were reported. The number of reported items ranged from 5 (14.3%) and 24 (68.6%) across the guidelines (Figure 2).

The most frequently reported items among the 35 items in the RIGHT standard were item 5 (*i.e. Brief description of the health problem(s)*) and item 13a (*i.e. Provide clear, precise, and actionable recommendations*) which were both reported in 14 (93.3%) guidelines. These were followed by 11a (*i.e. Indicate whether the guideline is based on new systematic reviews done specifically for this guideline or whether existing systematic reviews were used*), which were reported in 13 (86.7%) guidelines. None of the guidelines reported item 6 (*i.e. Describe the aim(s) of the guideline and specific objectives, such as improvements in health indicators, quality of life, or cost savings*), 9a (*i.e. Describe how all contributors to the guideline development were selected and their roles and responsibilities.*), 11b (*i.e. If the guideline developers used existing systematic reviews, reference these and describe how those reviews were identified and assessed and whether they were updated*), 18b (*i.e. Describe the role of funder(s) in the different stages of guideline development and in the dissemination and implementation of the recommendations*) or 22 (*i.e. Describe any limitations in the guideline development process (such as the development groups were not multidisciplinary or patients' values and preferences were not sought), and indicate how these limitations might have affected the validity of the recommendations*). (Table.2).

The reporting proportion of the 7 domains (*i.e. Basic information, Background, Evidence, Recommendations, Review and quality assurance, Funding and declaration and management of interests and Other information*) in RIGHT standards were 46.7%, 40.8%, 45.3%, 29.5%, 53.3%, 10.0%, 26.7%, respectively.

DISCUSSION

Among the fifteen guidelines included, the reporting proportion of 14 guidelines were less than 50%, only one guideline reported the items with the rate more than 50%. Most of the guidelines in this analysis were of low reporting quality. Items related to the description of the health problems, health care questions, recommendations or other key contents of the guidelines, were often well reported. However, when it comes to the items related to the details of the guideline development process, such as how the outcomes were selected and sorted, specific sources of funding for all stages of guideline development, or the role of funders in the different stages of guideline development, the reporting proportion tended to be low. This finding is consistent with the study by Chen et al.^[30]

The reporting proportion of the domain “*basic information*” was comparatively high among all the 7 domains, but there were still many details which needed improvement. For example, in the item “*Identify the report as a guideline, that is, with ‘guideline(s)’ or ‘recommendation(s)’ in the title.*” (Item 1a), 5 guidelines (33.3%) could not be identified as a guideline by its title. If a guideline uses an uncommon term or does not report this information in the title, it will be difficult for researchers and practitioners to retrieve it from a database nor identify it as a practice guideline.^[31] Eight guidelines summarized the recommendations, but only two guidelines summarized the recommendations in the executive summary as required by item 2 (*i.e. “Executive summary”, “Provide a summary of the recommendations contained in the guideline”*). Summarizing and presenting recommendations in the executive summary helps the guideline users to obtain the key information quickly and effectively, and hence improves the efficiency of reading and using the

guidelines, as well as its dissemination and implementation. Therefore, it is necessary and meaningful to promote and strengthen the reporting of this item.

In the domain of "background," the reporting proportion of items 7a (10, 66.7%), 8a (6, 40.0%) and 8b (3, 20.0 %), which are related to the target population, scope, and users of the guidelines, were not high enough. Reporting the setting, target audience and users of the guideline determines whether the guideline can be used and implemented accurately. For example, the recommendations of a guideline whose setting was "UK healthcare settings" would not necessarily be valid in Asia and other geographic locations, given the potential differences in patient characteristics and regional/national conditions. A guideline can be applied properly only for the target population and settings, otherwise the recommendations of which may sometimes result in counterproductive effects. This is also why a revised version of a guideline is necessary when the settings or audience are different compared with the original one.^[32]

The reporting proportion of items in the domain "evidence" was low. Several studies used AGREE II to evaluate the methodological quality of guidelines, finding that the quality in items related to this domain was also low, especially for evidence identification and evaluation.^[33-36] The low quality of reporting may be one of the reasons for the result of the poor methodological evaluated by AGREE II. Because the assessment of the methodological quality of the guideline depends on the content and form of the reporting to some extent.^[36, 37] However, it is regrettable that some guidelines did not report relevant information in the text even if relevant actions (such as the process of searching systematic reviews and the search strategies) were carried out during the guideline development process.^[38] In this domain, item 11b is particularly complicated. It includes several judgments on whether the guideline reported the search strategies, the selection criteria and the evaluation of the risk of bias, and whether they were updated. The judgment of multiple factors in a single item will cause inconvenience to the researchers. Therefore, the RIGHT Working Group planned to expand the items related to systematic reviews,^[39] which would subsequently improve the convenience and operability of the use of the RIGHT checklist. In addition, it is worth noting that, in the field of assisted reproductive technology, the primary evidence is lacking, or relatively old. Thus some of the guidelines have only been partly, if at all, based on systematic reviews. In this situation, evaluating the reporting quality of the guidelines in the domain of "evidence" has been challenging.

Among the 15 guidelines included, the reporting proportion in the domain of "recommendations" was only 29.5%, especially in the three items related to the rationale and explanation of recommendations (i.e. items 14a, 14b and 14c). The reporting proportion were only 13.3%, 13.3%, and 6.7%, respectively. These items are necessary for the completeness of the guideline methodology. If this content is reported incompletely, the AGREE quality evaluation results of the guidelines would be affected.

The reporting proportion in the domain of "review and quality assurance" was the highest among all seven domains. However, the completeness of the reporting on these items still needs to be improved, especially for the item 16 "*Indicate whether the draft guideline underwent independent review and, if so, how this was executed and the comments considered and addressed*", for which most of the guidelines reported only partially. Although 8 guidelines reported some relevant information, only three guidelines comprehensively reported the details of the reviewers, reviewing process, and feedback process. The guidelines should strengthen the integrity by reporting the reviewing process, as well as improving the reporting quality in this domain.

The domain of “*Funding and declaration and management of interests*” had been rarely reported among the seven domains, with a reporting proportion of less than 10%. In particular the item “*Describe the role of funder(s) in the different stages of guideline development and in the dissemination and implementation of the recommendations.*” (Item 18b) was poorly reported. This finding is consistent with the study by Xiaoqin et al ^[41]. Most of the guidelines did not take into account the dissemination and implementation process, and thus most of the reporting evaluation results were “not applicable”. This may be caused by the fact that the dissemination and implementation of the guidelines was often not managed by the guideline developers themselves.^[40] With the gaps between clinical practice and evidence reported by J Wilkinson et.al ^[42], we suggested the guideline developers consider the implementation and dissemination when developing a guideline and report them in the text, which may help the recommendations to be properly implemented and widely used.

In the domain of “other information”, nearly half of the guidelines reported the recommendations for future research and the limitations of the present evidence. This information helps the relevant researchers to determine the direction for further research.^[38] However, none of the included guidelines reported any limitations of the guidelines. Reporting these aspects can increase the credibility of the guideline, while also helping guideline users to select and use recommendations with necessary caution.

Strengths and limitations

We only searched the English databases and Chinese data bases in the study. Consequently, the result of this study did not cover all the guidelines of ART in other languages.

The main strength of this study lies in the fact that the researchers independently conducted a systematic search and evaluation. This is the first time that the RIGHT criteria were used to evaluate ART guidelines.

CONCLUSION

At present, the general quality of reporting of ART guidelines has been poorly conducted, especially regarding the declaration of funding and the acknowledgement of limitations. In future guideline development processes, consideration should be given to reporting the guidelines with reference to the RIGHT checklist ^[43], which not only helps improve the overall reporting quality, but also its dissemination and implementation.

Conflicts of interest

None declared.

Figure legends

Figure 1. Flowchart of systematic search.

Figure 2. The number of reported items of each guideline

Data sharing

No additional data are available

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Provenance and peer review

Not commissioned; externally peer reviewed

Patient and Public Involvement

No patients or public were involved

Acknowledgements

We thank our colleagues at the Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province for their help. We are also grateful to all researchers who devote to the study for their rigorous work.

Author contributions

YX and LJ are joint first authors. JH and CG searched the database, selected guidelines and extracted the main characteristics of the guideline. YX, YT and LL analyzed the data. YX drafted the manuscript. LJ, XL, LK, LY, QZ, JE and YC contributed to the interpretation of the results and critical revision of the manuscript for important intellectual content and approved the final version of the manuscript. All authors have read and approved the final manuscript. HS and YC are the study guarantors.

Funding

National Natural Science Foundation of China, Grant No. 81503459

Translation and Training Cooperation Base for Standards of Traditional Chinese Medicine of Belt and Road Initiative No. GZYYGJ2018042

REFERENCE

1. Zegershochschild F, Adamson G D, Dyer S, et al. The International Glossary on Infertility and Fertility Care 2017. *Hum Reprod* 2017, 108(3):393-406.
2. Gunnell DJ, Ewings P. Infertility prevalence, needs assessment and purchasing. *J Public Health Med* 1994, 16:29 – 35.
3. Templeton A, Fraser C, Thompson B. Infertility—epidemiology and referral practice. *Human Reprod* 1991, 6:1391 – 4.
4. Cowl J, Tyrrell H, Sakala C, et al. G-I-N PUBLIC Toolkit: Patient and Public Involvement in Guidelines. 2015.
5. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care* 2003, 12(1):18-23
6. About the AGREE Next Steps Consortium. <http://www.agree.trust.org/about-agree/agree-research-teams/agree-next-steps-consortium/>. (accessed 21 May 2013).
7. Oxman AD, Schunemann HJ, Fretheim A. Improving the use of research evidence in guideline development: 16. Evaluation. *Health Res Policy Syst* 2006, 4:28.
8. Wilson KC, Irwin RS, File TM Jr, et al. ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. Reporting and publishing guidelines: article 12 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. *Proc. Am Thorac Soc* 2012, 9:293-7.
9. Cui Shichao, Hou Haiyan, Li Youping, et al. Clinical Practice Guidelines on Infertility: A Systematic Review. *Chin J Evid-Based Med* 2013, 13(8):947-54.
10. Gutarra-Vilchez R B, Barajas-Nava L, Aleman A, et al. Systematic evaluation of the quality of clinical practice guidelines on the use of assisted reproductive techniques. *Hum Fertil (Camb)* 2014, 17(1):28-36.
11. Huwiler-Muhtenier K, Junn P, Junker C, et al. Quality of reporting of randomized trials as a measure of methodologic quality. *JAMA* 2002, 287:2801-4.
12. Enhancing the Quality and Transparency Of health Research. <https://www.equator-network.org/reporting-guidelines/right-statement/> (accessed 28 July 2018).
13. <http://www.right-statement.org/home/translations> (accessed 28 July 2018).
14. Chen Y, Yang K, Marusic A, et al. A reporting tool for practice guidelines in health care: the right statement. *Ann Intern Med* 2016;166 (2):128.
15. World Health Organization. Recommendations on the management of services for in vitro fertilisation from the WHO (regional office for Europe) 1990. *BMJ* 1992;305(6847):250-a.
16. Obstetricsgynaecologists RCO. Royal College of Obstetrics and Gynaecologists. Clinical Guideline no 4. The management of infertility in tertiary care. *BJU Int* 2001;87(3):213–7.
17. Thornhill AR, Dediesmulders CE, Geraedts JP, et al. ESHRE PGD Consortium ‘Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)’. *Hum Reprod* 2005;20(1):35-48.
18. Joint S C. Guidelines for the number of embryos to transfer following in vitro fertilization No. 182, September 2006. *Int J Gynaecol Obstet* 2008;102(2):203.
19. Practice Committee of the American Society for Reproductive Medicine, Practice Committee of the Society for Assisted Reproductive Technology. Guidelines on number of embryos transferred. *Fertility and Sterility* 2009;92(5): 1518-9.

20. Cutting R, Barlow S, Anderson R. Human oocyte cryopreservation: evidence for practice. *Hum Fertil (Camb)* 2009;12(3):125-36.
21. Min JK, Hughes E, Young D, et al. Elective single embryo transfer following in vitro fertilization. *J Obstet Gynaecol Can* 2010;32(4):363-77.
22. Alper M M. Boston IVF Handbook of Infertility - A Practical Guide for Practitioners Who Care for Infertile Couples, Third Edition. *CRC Press* 2011.
23. Practice Committees of American Society for Reproductive Medicine. Mature oocyte cryopreservation: a guideline. *Fertil Steril* 2013;99(1):37-43.
24. Fertility problems: assessment and treatment. <https://www.nice.org.uk/guidance/cg156/resources/fertility-problems-assessment-and-treatment-pdf-35109634660549> (accessed 28 July 2018).
25. National Collaborating Centre for Women's and Children's Health (UK). Fertility: Assessment and Treatment for People with Fertility Problems. *RCOG Press* 2013;1(4):21-8.
26. Okun N, Sierra S, Wilson R D, et al. Pregnancy Outcomes After Assisted Human Reproduction. *J Obstet Gynaecol Can* 2014;36(1):64-83.
27. Harbottle S, Hughes C, Cutting R, et al. Elective Single Embryo Transfer: an update to UK Best Practice Guidelines. *Hum Fertil (Camb)* 2015;18(3):165.
28. Practice Committee of the American Society for Reproductive Medicine. Performing the embryo transfer: a guideline. *Fertil Steril* 2017;107(4):882.
29. Guideline for diagnosis and treatment of infertility in advanced age women. *Chinese Journal of Reproduction & Contraception*, 2017.
30. Chen Renbo, Chen Yaolong, Gai Guozhong, et al. Analysis of reporting specification about sepsis practice guideline based on RIGHT standard. *China Journal of Chinese Materia Medica*. 2017, 42(8):1514-7.
31. Wei D, LR, Zhang HX, et al. How to search practice guideline efficiently: A systematic review. [abstract] G-I-N Conference. Amsterdam, Netherlands. 2015.
32. Hu Jing, Chen Ru, Xie Hongyan, et al. Adapting clinical practice guidelines scientifically and normatively. *Chin J Evid Based Pediatr* 2012;07(3):226-30.
33. Brosseau L, Rahman P, Toupinapril K, et al. A Systematic Critical Appraisal for Non-Pharmacological Management of Osteoarthritis Using the Appraisal of Guidelines Research and Evaluation II Instrument. *PLoS One* 2014;9(1):e82986.
34. Radwan M, Sari AA, Rashidian A, et al. Appraising the methodological quality of the clinical practice guideline for diabetes mellitus using the AGREE II instrument: a methodological evaluation. *JRSM Open* 2017;8(2):205427041668267.
35. Alonso-Coello P, Irfan A, Solà I, et al. The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies. *Qual Saf Health Care* 2010; 19(6):e58.
36. Tejani T, Mubeen S, Seehra J, et al. An exploratory quality assessment of orthodontic clinical guidelines using the AGREE II instrument. *Eur J Orthod* 2017;39(6).
37. Hayward R S, Wilson M C, Tunis S R, et al. Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The Evidence-Based Medicine Working Group. *JAMA* 1995;274(7):570-4.
38. Wang Q, Wang X, Chen Y, et al. Research Gap of Guidelines might be an important approach to prioritization. *J Clin Epidemiol* 2015: 69.

39. <http://www.right-statement.org/home/extensions> (accessed 28 July 2018).
40. Shekelle P, Woolf S, Grimshaw JM, et al. Developing clinical practice guidelines: reviewing, reporting, and publishing guidelines; updating guidelines; and the emerging issues of enhancing guideline implementability and accounting for comorbid conditions in guideline development. *Implement Sci* 2012;7(1):1-7.
41. Wang X, Chen Y, Yao L, et al. Reporting of declarations and conflicts of interest in WHO guidelines can be further improved. *J Clin Epidemiol* 2018; 98: 1-8.
42. Wilkinson J, Bhattacharya S, Jmn D, et al. Reproductive medicine: Still more ART than science? *BJOG* 2018.
43. <http://www.right-statement.org/right-statement/checklist> (accessed 28 July 2018).

Annex1

Search strategies (set the strategy of PubMed as an example)

PubMed

- #1. "Reproductive Techniques" [Mesh]
- #2. "Reproductive Techniques" [Title/Abstract]
- #3. "Reproduction Techniques" [Title/Abstract]
- #4. "assisted reproduction" [Title/Abstract]
- #5. "IVF" [Title/Abstract]
- #6. "ICSI" [Title/Abstract]
- #7. "in vitro fertilisation" [Title/Abstract]
- #8. "in-vitro fertilisation techniques" [Title/Abstract]
- #9. "in-vitro fertilization techniques" [Title/Abstract]
- #10. "in vitro fertilization" [Title/Abstract]
- #11. "in vitro maturation" [Title/Abstract]
- #12. "intracytoplasmic sperm injection" [Title/Abstract]
- #13. "IUI" [Title/Abstract]
- #14. "Intrauterine Insemination" [Title/Abstract]
- #15. "Embryo Transfer" [Title/Abstract]
- #16. "fertilization in vitro" [Title/Abstract]
- #17. "fertilisation in vitro" [Title/Abstract]
- #18. "intra cytoplasmic sperm injection" [Title/Abstract]
- #19. "embryo culture techniques" [Title/Abstract]
- #20. "blastocyst injection" [Title/Abstract]
- #21. OR/#1- #21
- #22. "Practice guideline" [Publication Type]
- #23. "Consensus Development Conference" [Publication Type]
- #24. "Recommendation" [Title/Abstract]
- #25. guid*[Title/Abstract]
- #26. "Best Practice" [Title/Abstract]
- #27. "statement" [Title/Abstract]
- #28. OR/#22- #27
- #29. #22 AND #25

Annex 2

RIGHT Checklist

Section/Topic	Number	Item
Basic information		
Title/subtitle	1a	Identify the report as a guideline, that is, with “guideline(s)” or “recommendation(s)” in the title.
	1b	Describe the year of publication of the guideline
	1c	Describe the focus of the guideline, such as screening, diagnosis, treatment, management, prevention, or others.
Executive summary	2	Provide a summary of the recommendations contained in the guideline.
Abbreviations and acronyms	3	Define new or key terms, and provide a list of abbreviations and acronyms if applicable
Corresponding developer	4	Identify at least 1 corresponding developer or author who can be contacted about the guideline.
Background		
Brief description of the health problem(s)	5	Describe the basic epidemiology of the problem, such as the prevalence/incidence, morbidity, mortality, and burden (including financial) resulting from the problem.
Aim(s) of the guideline and specific objectives	6	Describe the aim(s) of the guideline and specific objectives, such as improvements in health indicators (e.g., mortality and disease prevalence), quality of life, or cost savings.
	7a	Describe the primary population(s) that is affected by the recommendation(s) in the guideline.
	7b	Describe any subgroups that are given special consideration in the guideline
Target population(s)	8a	Describe the intended primary users of the guideline (such as primary care providers, clinical specialists, public health practitioners, program managers, and policymakers) and other potential users of the guideline.
	8b	Describe the setting(s) for which the guideline is intended, such as primary care, low- and middle-income countries, or inpatient facilities
End users and settings	9a	Describe how all contributors to the guideline development were selected and their roles and responsibilities (e.g., steering group, guideline panel, external reviewers, systematic review team, and methodologists).
	9b	List all individuals involved in developing the guideline, including their title, role(s), and institutional affiliation(s).
Evidence		
Health care questions	10a	State the key questions that were the basis for the recommendations in PICO (population, intervention,

		comparator, and outcome) or other format as appropriate.
	10b	Indicate how the outcomes were selected and sorted.
	11a	Indicate whether the guideline is based on new systematic reviews done specifically for this guideline or whether existing systematic reviews were used.
Systematic reviews	11b	If the guideline developers used existing systematic reviews, reference these and describe how those reviews were identified and assessed (provide the search strategies and the selection criteria, and describe how the risk of bias was evaluated) and whether they were updated.
Assessment of the certainty of the body of evidence	12	Assessment of the certainty of the body of evidence
Recommendations		
	13a	Provide clear, precise, and actionable recommendations
	13b	Present separate recommendations for important subgroups if the evidence suggests that there are important differences in factors influencing recommendations, particularly the balance of benefits and harms across subgroups.
Recommendations	13c	Indicate the strength of recommendations and the certainty of the supporting evidence.
	14a	Describe whether values and preferences of the target population(s) were considered in the formulation of each recommendation. If yes, describe the approaches and methods used to elicit or identify these values and preferences. If values and preferences were not considered, provide an explanation.
Rationale/explanation for recommendations	14b	Describe whether cost and resource implications were considered in the formulation of recommendations. If yes, describe the specific approaches and methods used (such as cost-effectiveness analysis) and summarize the results. If resource issues were not considered, provide an explanation.
	14c	Describe other factors taken into consideration when formulating the recommendations, such as equity, feasibility, and acceptability.
Evidence to decision processes	15	Describe the processes and approaches used by the guideline development group to make decisions, particularly the formulation of recommendations (such as how consensus was defined and achieved and whether voting was used).
Review and quality assurance		
External review	16	Indicate whether the draft guideline underwent

		independent review and, if so, how this was executed and the comments considered and addressed
Quality assurance	17	Indicate whether the guideline was subjected to a quality assurance process. .If yes, describe the process
Funding and declaration and management of interests		
Funding source(s) and role(s) of the funder	18a	Describe the specific sources of funding for all stages of guideline development.
	18b	Describe the role of funder(s) in the different stages of guideline development and in the dissemination and implementation of the recommendations.
Declaration and management of interests	19a	Describe what types of conflicts (financial and nonfinancial) were relevant to guideline development.
	19b	Describe how conflicts of interest were evaluated and managed and how users of the guideline can access the declarations
Other information		
Access	20	Describe where the guideline, its appendices, and other related documents can be accessed.
Suggestions for further research	21	Describe the gaps in the evidence and/or provide suggestions for future research.
Limitations of the guideline	22	Describe any limitations in the guideline development process (such as the development groups were not multidisciplinary or patients' values and preferences were not sought), and indicate how these limitations might have affected the validity of the recommendations

RIGHT = Reporting Items for practice Guidelines in Healthcare